Compare JOB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOB | LSTA |
|---|---|---|
| Founded | 1893 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 20.9M |
| IPO Year | N/A | N/A |
| Metric | JOB | LSTA |
|---|---|---|
| Price | $0.19 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 210.2K | 23.8K |
| Earning Date | 12-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $108,752,000.00 | $1,070,000.00 |
| Revenue This Year | $43.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $1.81 |
| 52 Week High | $0.51 | $4.20 |
| Indicator | JOB | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 43.92 |
| Support Level | $0.18 | $1.85 |
| Resistance Level | $0.19 | $2.15 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 96.63 | 48.44 |
GEE Group Inc is a provider of specialized staffing solutions across the United States. The company's operating segment includes Industrial Staffing Services and Professional Staffing Services. It generates maximum revenue from the Professional Staffing Services segment. The company provides the following services, direct hire placement services, temporary professional services staffing in the fields of information technology, accounting, finance and office, engineering, and medical, and temporary light industrial staffing.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.